Quantum Biopharma (QNTM) Accumulated Expenses (2024 - 2025)
Quantum Biopharma (QNTM) reported Accumulated Expenses of $2.2 million for Q4 2025, up 98.71% on a YoY basis from $1.1 million in Q4 2024, and up 98.71% sequentially from $1.1 million in Q4 2024.
Quantum Biopharma (QNTM) Accumulated Expenses (2024 - 2025) Analysis & Trends
Quantum Biopharma (QNTM) has 2 years of Accumulated Expenses data on file, last reported at $2.2 million in Q4 2025.
- For the quarter ending Q4 2025, Accumulated Expenses rose 98.71% year-over-year to $2.2 million; the trailing twelve-month figure through Dec 2025 stood at $2.2 million (up 98.71% YoY), and the FY2025 full-year result was $2.2 million, up 98.71% from the prior year.
- Accumulated Expenses improved to $2.2 million in Q4 2025, from $1.1 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $2.2 million in Q4 2025 to a low of $1.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Quantum Biopharma | 2.61 Bn | 2.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.20 Mn |
| Dec 31, 2024 | 1.11 Mn |